title: A review of  iniparib  in ovarian cancer.
abstract: BACKGROUND
  Patients with metastatic ovarian cancer continue to experience high recurrence rates and significant morbidity from standard treatments. There is a great need for efficacious tumor-specific agents in ovarian cancer. Iniparib (BSI-201) is a targeted drug currently under investigation.
  
  
  METHODS
  The authors identified the mechanistic and clinical data available on the role of iniparib in ovarian cancer. Iniparib was initially thought to act via the poly-ADP ribose polymerase 1 (PARP-1) pathway, but recent studies have shown only nonspecific interactions between the drug and PARP proteins. Although iniparib is only active in cancer cells, the exact mechanism of action remains unclear. Iniparib was well tolerated at all dose levels in Phase I studies of solid organ malignancies. Preliminary data from Phase II studies of iniparib for the treatment of platinum-sensitive and platinum-resistant recurrent ovarian cancer show improvement in survival compared to historic controls. There are currently no Phase III studies.
  
  
  CONCLUSIONS
  Iniparib shows promise in early clinical trials; however, understanding the pathways of cytotoxicity will be crucial as cancer therapy becomes increasingly individualized.
authors: Washington University in St Louis, Campus Box 8064, 4th floor maternity, 4911 Barnes Jewish Hospital Plaza, St Louis, MO 63110, USA. ivywilkry@gmail.com
authors: Ivy
authors: I
authors: Wilkinson-Ryan
authors: David
authors: D
authors: Mutch
mesh_terms: D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism
chemical_list: D001549:Benzamides; C090712:iniparib; D011065:Poly(ADP-ribose) Polymerases